Smith & Nephew SNATS, Inc. (SNN): Price and Financial Metrics
Smith & Nephew SNATS, Inc. (SNN)
Today's Latest Price: $43.67 USD
Updated Jan 27 7:00pm
Add SNN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 189 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
SNN Stock Summary
- With a market capitalization of $20,173,876,031, Smith & Nephew Plc has a greater market value than 89.41% of US stocks.
- With a year-over-year growth in debt of 38.31%, Smith & Nephew Plc's debt growth rate surpasses 78.86% of about US stocks.
- In terms of volatility of its share price, SNN is more volatile than merely 2.28% of stocks we're observing.
- Stocks that are quantitatively similar to SNN, based on their financial statements, market capitalization, and price volatility, are STE, COO, CBRE, GIB, and AJG.
- Visit SNN's SEC page to see the company's official filings. To visit the company's web site, go to www.smith-nephew.com.
SNN Stock Price Chart Interactive Chart >
SNN Price/Volume Stats
| Current price | $43.67 | 52-week high | $52.26 |
| Prev. close | $45.58 | 52-week low | $26.07 |
| Day low | $43.63 | Volume | 479,800 |
| Day high | $44.60 | Avg. volume | 386,206 |
| 50-day MA | $41.77 | Dividend yield | 1.23% |
| 200-day MA | $40.31 | Market Cap | 19.15B |
Smith & Nephew SNATS, Inc. (SNN) Company Bio
Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. The Company operates in two segments: Advanced Surgical Devices and Advanced Wound Management. The company was founded in 1856 and is based in London, the United Kingdom.
SNN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $43.67 | $9.36 | -79% |
We started the process of determining a valid price forecast for Smith & Nephew Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Smith & Nephew Plc ranked in the 19th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 79.33%. The most interesting components of our discounted cash flow analysis for Smith & Nephew Plc ended up being:
- The company has produced more trailing twelve month cash flow than 78.67% of its sector Healthcare.
- The business' balance sheet reveals debt to be 5% of the company's capital (with equity being the remaining amount). Approximately only 16.9% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- SNN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 43.13% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -80% |
| 1% | -80% |
| 2% | -79% |
| 3% | -79% |
| 4% | -79% |
| 5% | -79% |
Want more companies with a valuation profile/forecast similar to that of Smith & Nephew Plc? See GMED, CNMD, LMNX, VAR, and EHC.
Loading social stream, please wait...